Sumitomo Bakelite Company Limited

Hokkaido University

Hitachi-high-technologies Corporation

Shionogi Company Limited

Medicinal Chemistry Pharmaceuticals Co., Ltd.

Hitachi, Ltd.

Kao Corporation

Murata Kikai Kabushiki Kaisha

Toyobo Co., Ltd.

Carna Biosciences, Inc.

Shinichiro Nishimura

Hiroaki Nakagawa

Kisaburo Deguchi

Hideyuki Shimaoka

Yoshiaki Miura

Yasuro Shinohara

Masahito Ito

Kuriko Yamada

Jun-ichi Furukawa

Masanori Takaki

Kenichi Niikura

Risho Miyoshi

Kentaro Naruchi

Minenobu Okayama

Masakazu Tanaka

Genzou Hirata

Hiroshi Yamazaki

Shintaro Inoue

Junkichi Miura

Ichiro Azuma

Susumu Nishiguchi

Seiichi Tokura

Hideki Moriyama

Atsushi Toda

Hiromitsu Kuramoto

Mariko Hara

Yasuhiro Takegawa

Takahiro Tsukida

Koichi Yokota

Hiroshi Seo

Genzo Hirata

Mika Nakano

Yoko Kita

Michio Horiuchi

Toshiharu Kuroda

Masahiro Yoshida

Masaharu Sato

Kyoko Fukunaga

Fumio Nakajima

Rie Uematsu

Mariko Hatakeyama

Hiroaki Motoki

Jun-Ichi Furukawa

The present invention provides: an antibody that has specificity for MUC 4 having a sugar chain structure that is expressed at a high level in cancer cells; a glycopeptide that constitutes an antigen that is suitable for producing this antibody; and a new means and method for the diagnosis, prevention, and/or treatment of cancer by means of the aforementioned antibody. The present invention relates to a monoclonal antibody against a glycopeptide. The glycopeptide comprises a human MUC 4 tandem unit peptide having an amino acid sequence represented by SEQ ID NO: 1, and an O-linked sugar chain. The O-linked sugar chain is N-acetylgalactosamine (GalNAc) and binds to threonine, which is the 8th amino acid of the tandem unit peptide. The present invention further includes: a glycopeptide for use in the production of a monoclonal antibody against human MUC 4; a method for detecting MUC 4 in a human body fluid sample; a kit that includes the abovementioned monoclonal antibody; and a pharmaceutical composition for the prevention and/or treatment of malignant tumors that contains the abovementioned monoclonal antibody as an active component.

Antibody to mucin 4 (MUC4) glycopeptide and uses thereof

The present invention provides: an antibody exhibiting specificity for MUC1, the antibody having a glycan structure expressed at high levels in cancer cells; a method for manufacturing this antibody; and a novel means and method for the diagnosis and prevention and/or treatment of cancer using this antibody. The present invention is a monoclonal antibody to human MUC1, wherein the antibody specifically recognizes a glycopeptide having a human MUC1 tandem unit and furthermore having an O-linked glycan core (0(Tn)) in any one of the threonine and serine in the amino acid sequence of this human MUC1 tandem unit. A method for detecting MUC1 in a human body-fluid sample. A kit including this monoclonal antibody. A pharmacological composition for the prevention and/or treatment of a malignant tumor, the pharmacological composition containing this monoclonal antibody as an active ingredient.

Anti-MUC1 antibody or antigen-binding fragment thereof and uses thereof

The present invention provides a method for preparing a sample characterized by binding a substance A containing a hydrazide group to a sugar chain and/or a sugar derivative via hydrazone formation between the hydrazide group of the substance A and the reducing end of the sugar chain and/or the sugar derivative thereby to enable the separation and purification of the sugar chain and/or the sugar derivative for an analytical sample from a biological sample containing the sugar chain and/or the sugar derivative by a simple operation.

Sugar chain-capturing substance and use thereof

The present invention provides substance which can specifically interact with sugar chains. Further, the present invention provides a method for separating, concentrating, or purifying sugar chains or a sugar chain-containing substance in a sample, comprising the steps of: a) contacting a sugar chain-trapping carrier comprising a substance which can specifically interact with sugar chains with the sample in a fluid phase under conditions that the sugar chain-trapping carrier can react with the sugar chains or sugar chain-containing substance; b) isolating a composite of the sugar chain-trapping carrier and the sugar chains or sugar chain-containing substance from the fluid phase; and c) exposing the composite to the conditions that the interaction between the sugar chain-trapping carrier and the sugar chains or sugar chain-containing substance is at least partially eliminated.

Method of purifying/concentrating sugar chains with a sugar chain-trapping molecule and method of analyzing sugar chain structure

Method of purifying/concentrating sugar chain with sugar chain-trapping molecule and method of analyzing sugar chain structure

To provide an autoanalyzer for analyzing a sugar chain contained in a biological sample, in particular, serum. Namely, it is intended to provide a method of analyzing a sugar chain in a sample, which comprises the following steps: A) the sugar chain-releasing step of releasing the sugar chain in the sample; B) the detection sample-preparing step of preparing the released sugar chain for detection; and, in the case of conducting mass spectrometry using a plate, C) the step of forming a plate for the mass spectrometry having the captured sugar chain dotted thereon which comprises the step of providing the tagged sugar chain sample solution obtained in the step B) on a collection plate; and, if required, the step of conducting an operation in a solid phase support-enclosed plate to form the plate for mass spectrometry; and D) the step of analyzing the sugar chain to be assayed.

Apparatus for auto-pretreating sugar chain

After various sugar nucleotide solutions and glycosyltransferases (or primers) have been mixed, they are introduced into a reaction tank (column) with primers (or glycosyltransferases) immobilized thereon. Then solutions coming out of the reaction tank are led to an ultrafiltration column. The oligosaccharide synthesizer according to the present invention is equipped with a flow path for ensuring that glycosyltransferases or primers separated by the ultrafiltration column are returned into a container for storing each solution in a sample injector.

Oligosaccharide synthesizer

A support comprising functional groups supported therein that specifically react with an aldehyde group of a sugar chain, and a polymer particle and a glycochip to which the support is applied, and uses thereof.

Polymer particle

A method for preparing an analysis sample which involves the sugar chain capture step comprising a reaction of capturing a sugar chain and/or a sugar derivative from a biological sample by using a sugar chain capture agent and the excision step comprising excising a compound containing a moiety capturing the sugar chain and/or the sugar derivative from the sugar chain capture agent after the completion of the sugar chain capture reaction and releasing the compound.

Method for preparing analysis sample, analysis sample and sugar chain capture agent

An oxylamino group-containing compound represented by the following formula:R&#x2014;B-A-B&#x2014;R,wherein Rrepresents a polymerizable group, Rrepresents an oxylamino group-containing group or an oxylamino derivative-containing group, B represents an ester linkage or an amide linkage, and A represents an optionally substituted alkylene group having 2 to 12 carbon atoms.

Oxylamino group-containing compound and polymer

The present invention provides a sugar chain synthesizer capable of continuously reacting sugar chains when a plurality of sugar chains are successively reacted. The sugar chain synthesizer of the present invention includes a plurality of vessels containing respective sugar nucleotide solutions, a plurality of vessels containing respective glycosyltransferases, and a reactor containing a primer that is a water-soluble polymer, into which the above described sugar nucleotide solution and glycosyltransferase are introduced. In the present invention, components in a reaction solution obtained in the reactor are separated through an ultrafiltration column, and a reaction product is then returned to the above described reactor, so as to continuously synthesize sugar chains. Although it is a complicated synthesis of sugar chains, it becomes possible to carry out such synthesis continuously and automatically.

Saccharide composition synthesizer

It is intended to chemically synthesize the trisaccharide moiety at the reducing end in the core sugar chain structure of an asparagine-linked glycoprotein. By using a highly inexpensive natural polysaccharide having a mannose&#x3b2;-1,4-bond as the starting material, a &#x3b2;-1,4-glycoside bond of mannose is formed.

Synthesis of core sugar chain structure of asparagine-linked glycoprotein

The present invention provides a sugar chain purification instrument which can continuously and efficiently purify the sugar chain. According to the present invention, the instrument includes an immobilized protease column in which a carrier which can be packed in the column and on which protease is immobilized is packed and an immobilized glycopeptidase column in which a carrier which can be packed in the column and on which glycopeptidase is immobilized is packed, these columns being connected in series, and the reaction is carried out while continuously passing a glycoprotein to be decomposed together with a suitable buffer solution through the above columns. The step of liberation of sugar chain from the glycoprotein is highly simplified and labor-saving, and liberation of the sugar chain can be moderately and simply performed.

Saccharide composition purification instrument

A novel azasugar derivative, and a drug containing the same as an active ingredient are disclosed. The drug is useful for treatment of keratinocyte-proliferative diseases.

Azasugar derivative and drug containing the same as the active ingredient

Growing community of inventors

Sapporo, Japan

Shinichiro Nishimura